Randomized study of fentanyl citrate versus Oxycodone Hydrochloride Hydrate in patients with unresectable advanced pancreatic cancer

Randomized study of fentanyl citrate versus Oxycodone Hydrochloride Hydrate in patients with unresectable advanced pancreatic cancer - FRONTIER

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011756

Enrollment

Registered

2013-09-13

Start date

2013-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced pancreatic cancer

Interventions

Arm A:Oxycodone hydrochloride hydrate 10mg every 12 hours Arm B: Transdermal fentanyl citrate 1mg once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: unresectable advanced pancreatic cancer The case judged that 15-25mg oxycodone hydrochloride hydrate or more per day is required to cancer pain

Exclusion criteria

Exclusion criteria: serious liver, kidney, cardiac disorders, pulmonary impairment, and nervous system and psychic disorders

Design outcomes

Primary

Measure	Time frame
The rates of gastrointestinal disorders events in four weeks	—

Secondary

Measure	Time frame
quality of life,the rates of opioid rotation,pain score,the period until stable pain control ,overall survival time, The rates of adverse event	—

Countries

Japan

Contacts

Public ContactMinori Odanaka

National Cancer Center Hospital Clinical Trial Support Office

modanaka@ncc.go.jp03-3547-5201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026